Treatment-Emergent Psychosis With Aripiprazole

View This PDF

NB: This article is only available as a PDF.

Because this piece has no abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: Aripiprazole, the latest atypical antipsychotic to receive approval by the U.S. Food and Drug Administration, is unique in its action as a partial agonist at dopamine receptors.1 Partial agonists can function as net agonists or net antagonists, depending on the amount of naturally occurring full agonist neurotransmitter that is present. Aripiprazole has antagonist activity at dopamine-2 (D2) receptors in a hyperdopaminergic environment and agonist activity in a hypodopaminergic environment.​

J Clin Psychiatry 2005;66(10):1339